Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Eli Lilly

Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases. Its main offerings include pioneering scientific breakthroughs and expanding access to their medicines, with the ultimate goal of preventing and curing disease.

Novo Nordisk

Eventide Asset Management, LLC is a Boston-based investment adviser practicing ''investing that makes the world rejoice®.''​ Founded in 2008, Eventide's vision is to serve individuals, financial advisors, and institutions by providing high-performance investments that we believe create compelling value for the global common good.

Eventide

DexCom is a developer of glucose sensing technologies and focuses on these technologies. Founded in 1999, DexCom's roots stem from the pioneering 1967 research on implanted glucose sensors at the University of Wisconsin. DexCom started with a focus on creating an implantable Sensor that the body would not reject and that would perform for a long period of time.

Dexcom

ArrowMark Partners is an SEC-registered investment adviser. It aims to provide consistent, asymmetric, non-correlated, risk-adjusted returns by utilizing fundamental research across the capital structure. They are committed to compounding wealth by providing one-of-a-kind, client-driven, and absolute return solutions.

ArrowMark Partners

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.  Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016.  The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics.  The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma

Zealand Pharma

RTW Investments makes investments in forward-thinking healthcare companies. It invests across the entire company lifecycle, including company creation, early-stage venture capital, alternative financing, and public company investments.  The company is headquartered in New York with offices in London and Shanghai.

RTW Investments

LifeSci Venture Partners is an early-stage investment firm that invests in early-stage life sciences and healthcare companies. The firm provides companies in the life sciences industry with comprehensive solutions to communications and investor outreach. Their investment principals have broad-ranging life sciences experience including public and private investing, deal structuring, investment banking, equity capital markets, equity research, and bench research both basic science and applied.

LifeSci Venture Partners

Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.

Perceptive Advisors

Soleus Capital

Farallon Capital Management, L.L.C. is an American capital management firm that manages funds on behalf of institutions and individuals with significant capital. Based in San Francisco, the firm was founded by Thomas F. Steyer in March of 1986. As of September 2008, it has around 150 employees.  While it invests across the capital structure and in all asset classes, a large amount of its investments are in risk arbitrage, restructuring and recapitalization. Investments include public and private debt and equity securities, direct investments in private companies, and real estate. Farallon's real estate investments span the United States, Europe, Latin America and India.

Farallon Capital Management

Pura Vida Investments is a fundamentally driven, market neutral healthcare-focused investment vehicle. The objective of the firm is to identify and capitalize on structural changes in the healthcare landscape and on inflections in company specific valuations. The firm strives to look past day-to-day volatility and to hone in on major value shifts over the medium to longer term.  The firm’s portfolio is managed by Efrem Kamen and Doron Junger MD and is run in a market neutral fashion, investing across most areas of healthcare, including medical devices, biotechnology, pharmaceuticals, tools, life sciences and healthcare services. The Fund has an optional 10% allocation to designated investments, allowing participation in private and certain illiquid public securities, which is managed by Frank Litvack MD.

Pura Vida Investments

Omega Funds is a venture capital firm that seeks to invest in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS sectors.

Omega Funds

Sands Capital is an active, long-term investor in innovative growth businesses. The approach combines rigorous fundamental analysis with inspired thinking to seek out businesses that are creating the future. They operate through two affiliates: Sands Capital Management, which focuses on investing in companies in the public market, and Sands Capital Ventures, which focuses on investing in companies in the private market. By enabling clients to participate in the growth of these businesses, its mission is to add value and enhance their wealth with prudence over time.

Sands Capital Ventures

Marshall Wace is a hedge fund manager specializing in global long/short equity. The firm has investment management offices in London; New York; and Hong Kong.  Marshall Wace LLP was named Management Firm of the Year by the EuroHedge Awards 2011, reflecting the strong performance delivered by a number of our funds during the year. The firm is dedicated to the objective of providing its clients with a persistent, risk-adjusted return on their investment. Through a range of products, investors can select funds offering variable sources of alpha and beta, in different combinations, from equity markets around the world. Marshall Wace brings together two distinct but complementary approaches to asset management. First, traditional, fundamental long/short investing grounded in stock-specific analytical research, and secondly, Marshall Wace TOPS (‘MW TOPS’), the pioneering, and proprietary, systematic, alpha capture strategy.

Marshall Wace

Beta Bionics

Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.

Beta Bionics, a medical technology company, developed the iLet Bionic Pancreas for people with type 1 diabetes. It is an automated system that can deliver insulin in one or two hormone modes, automatically calculating and administering all insulin doses needed. The FDA-approved iLet Bionic Pancreas eliminates traditional setup, carbohydrate counting, correction, and bolus calculation.&nbsp;

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Beta Bionics Announces Partnership With Abbott to Integra...

Beta Bionics, a medical technology company, developed the iLet Bionic Pancreas for people with type 1 diabetes. It is an automated system that can deliver insulin in one or two hormone modes, automatically calculating and administering all insulin doses needed. The FDA-approved iLet Bionic Pancreas eliminates traditional setup, carbohydrate counting, correction, and bolus calculation.&nbsp;The system is compatible with two continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM. It is a pocket-sized, wearable medical device that uses ML algorithms to control blood sugar levels in people with diabetes. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a dual-hormone bionic pancreas.Key customers and partnershipsThe company has collaborated with pharmaceutical companies to improve its lead technology: <a href="https://www.betabionics.com/zealand-and-beta-bionics-to-collaborate-on-the-development-of-a-first-in-class-dual-hormonal-bionic-pancreas-system-for-treatment-of-people-with-type-1-diabetes/">Zealand Pharma</a> (June 2016) to develop a new dual-hormonal artificial pancreas system for the treatment of diabetes and <a href="https://www.betabionics.com/beta-bionics-and-convatec-announce-partnership-to-bring-unomedical-infusion-set-portfolio-to-the-ilet-bionic-pancreas-system/">ConvaTec</a> (July 2019) to manufacture infusion sets for use with Beta Bionics' iLet Bionic Pancreas System, which autonomously controls blood sugar levels in people with diabetes.&nbsp;Funding and financialsIn August 2023, the company raised USD 100 million in <a href="https://sp-edge.com/updates/21628">Series D funding</a> co-led by Sands Capital and Omega Funds to expand access to the iLet Bionic Pancreas across the US and further develop and test the bi-hormonal bionic pancreas.

Cardiomo Care is developing noninvasive wearable devices to alert users and caretakers when there are abnormalities in the heartbeat. The company’s AI engine, trained on existing and growing data sets, can predict potential heart issues up to two hours before they occur, enabling early detection and intervention for arrhythmias and other cardiovascular diseases (CVDs).The company's product, CardiomoPatch, is a waterproof, wearable patch capable of long-term wear with a 10-day battery life. The patch monitors a patient's cardiac data, including ECG outputs, breathing, and skin temperature, and transmits the data via a mobile app for analysis by Cardiomo's AI engine.&nbsp;As of May 2024, the company is yet to commercialize its product and has over 1,600 pre-orders.

Cardiomo Care

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Omada Health

VillageMD provides primary care services for patients. It also provides tools, technology, and staffing support needed for physicians to deliver high-quality services. VillageMD’s service delivery methods include traditional freestanding clinics, Village Medical at Walgreens co-located clinics, as well as at-home and around-the-clock virtual visits. It also leverages a team-based approach to care where physicians lead nurse practitioners, pharmacists, mental health specialists, and dietitians to offer a holistic care program. The technology of VillageMD includes docOS, an operating system that enables better patient care by connecting various clinical source systems with ongoing patient-generated data coupled with an AI engine to continuously analyze messages to enable patient self-care.The company made several acquisitions to expand its footprint: 1) <a href="https://sp-edge.com/updates/14347">Summit Health</a> for USD 8.9 billion in November 2022, 2) Healthy Interactions, an interactive patient education platform, in February 2022, and 3) <a href="https://sp-edge.com/updates/16968">Starling Physicians</a>, a primary care and specialty care provider, in March 2023.Key customers and partnershipsIn June 2020, VillageMD and Walgreens Boots Alliance announced a collaborative effort to open at least 600 Village Medical centers at Walgreens across more than 30 US markets by 2025. Walgreens invested USD 5.2 billion in VillageMD (from the previously announced USD 1.0 billion), raising its ownership stake to 63% (from 30%).However, as of May 2024, Walgreens had plans to close 160 VillageMD clinics as part of a cost-cutting plan.

VillageMD

Cityblock Health is a value-based healthcare provider focused on delivering comprehensive care to underserved communities, primarily Medicaid and lower-income Medicare beneficiaries. The company combines primary care, behavioral health, and social services to address the complex physical, mental, and social needs of its members.Cityblock's model involves partnering with local community-based organizations and deploying multidisciplinary care teams that include doctors, nurses, behavioral health specialists, and community health workers. These teams provide personalized care through 24/7 access to multi-modal care delivery, including in-home visits, telehealth, and community health hubs.The services of Cityblock are available to members at no additional cost if they are covered by an eligible health plan.Key Customers and PartnershipsAs of May 2024, the company’s services were available in seven states across the US and served over 100,000 members.In May 2024, it partnered with <a href="https://sp-edge.com/updates/29647">Sunshine Health</a> to expand to Florida, and, in <a href="https://sp-edge.com/updates/13270">September 2022</a>, it partnered with MDwise to expand into Indiana. Prior to that, the company had partnered with insurance providers such as ConnectiCare (Connecticut), Tufts Health Plan (Massachusetts), Emblem Health (New York), Healthy Blue (North Carolina), Molina Healthcare (Ohio) and CareFirst (Washington DC).Funding and FinancialsCityblock is a spin-off of Sidewalk Labs, an Alphabet company that incubates and invests in tech companies and products to improve urban infrastructure. It completed a USD 400 million Series D funding round led by Softbank in <a href="https://sp-edge.com/updates/5326">September 2021</a>, valuing the company at USD 5.7 billion. The funds were used to expand its services.

Cityblock Health

Everside Health (formerly Paladina Health) offers preventative care for chronic conditions and primary, mental and occupational healthcare treatments for acute conditions. Patients benefit from around-the-clock access to care, same-day or next-day appointments for in-person, and virtual care visits with zero copays.Everside aims to generate around 17% healthcare cost savings in three years and 31% in five years for its corporate members by leveraging a data-driven approach to care coordination.The company leverages data from past medical records, predictive analytics, and AI in the delivery of preventative care services.Founded in 2010 under the name Paladina Health, the company was rebranded in November 2020 as Everside Health following a merger between three primary care groups (Paladina, Activate Healthcare, and Healthstat). Furthermore, in February 2024, Everside Health merged with primary care provider Marathon Health to form a combined entity that would operate as Marathon Health, and, as of May 2024, the integration was ongoing.Key customers and partnershipPost-merger with Marathon Health, the combined entity would serve 2.5 million patients through over 680 clinics across 41 states.Funding and financialsThe company received its most recent investment in July 2022, amounting to USD 164 million in growth equity funding. The round was led by New Enterprise Associates (NEA). The funds were allocated toward growing its market presence and exploring opportunities for M&amp;A as well as to enhance and improve its product features. Additionally, the firm planned to expand its coverage of specialty care services aimed at individuals, employers, and union organizations.

Everside Health

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

To gather large amounts of real-time data for chronic care management, DTx, and patient monitoring

XR used by some startups for chronic pain management

Offers digital means of providing direct primary care, passive remote monitoring, chronic care management, etc.

AI/ML is used in predictive analytics, diagnostics tools, and population management

Offers tailored preventive interventions and treatments to the specific needs and characteristics of each individual

Massachusetts-based company Beta Bionics has raised $100 million in Series D funding to expand access to its iLet Bionic Pancreas across the US and further develop and test the bi-hormonal bionic pancreas. The funding was co-led by Sands Capital and Omega Funds, with participation from Marshall Wace and existing investors including Soleus Capital and Farallon Capital. Beta Bionics has developed the iLet Bionic Pancreas, an automated insulin delivery system that eliminates the need for traditional setup, carb counting, corrections, and calculating boluses. The iLet Bionic Pancreas uses adaptive, self-learning control algorithms with continuous glucose monitoring and pump technology.

Beta Bionics

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless